Deciphera Pharmaceuticals to Present at JMP Securities Life Sciences Conference

WALTHAM, Mass.–(BUSINESS WIRE)– Deciphera Pharmaceuticals, a clinical-stage biotechnology company
focused on developing advanced kinase inhibitor treatments targeting the
tumor cell and the tumor microenvironment, today announced that Michael
D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer will
present a corporate update at the upcoming JMP Securities Life Sciences
Conference on Tuesday, June 21, 2016 at 3:00 p.m. ET in New York.

About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals
seeks to improve treatment for patients with cancer by designing kinase
inhibitor therapies that target the hallmarks of cancer biology. We
specifically design our small molecule compounds to simultaneously block
multiple cancer signaling mechanisms in the tumor cell and the tumor
microenvironment to prevent growth and spread. Deciphera’s unique
approach represents an important advance over current therapies in the
durability of kinase inhibition and resiliency to genetic mutations to
provide greater benefit across a range of cancers. Deciphera’s business
strategy is to advance its drug candidates for genetically defined
cancers and cancers that target the tumor microenvironment through both
proprietary and partnered programs.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160616005142/en/